Drug intelligence / Profile preview

CPS-001

Development stage: Preclinical
Lead developer: CrossPoint Therapeutics
Modality: Small Molecules
Administration: Subcutaneous

Overview

CPS-001 is a discovery-stage immuno-oncology therapeutic candidate being developed by CrossPoint Therapeutics. It is built upon the company's proprietary Stealth-Body smart cell-targeting delivery technology, which is designed to deliver small molecule payloads to specific cellular targets. A key feature of CPS-001 is its immune-modulating activity coupled with a lack of Fc effector function, a design intended to optimize the delivery and safety profile of small molecule agents in the treatment of cancer.

Targets

CPS1 (Carbamoyl phosphate synthetase I)CPS1-IT1 (Carbamoyl-phosphate synthetase 1 intronic transcript 1)

Beyond the preview

Go deeper on CPS-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPS-001.

Explore the full profile